期刊文献+

中国慢性粒细胞白血病诊治现状和展望 被引量:6

原文传递
导出
摘要 慢性粒细胞白血病(CML)是一类发生在造血干细胞的以髓系细胞慢性增殖为主要特征的恶性克隆性疾病,95%的患者骨髓中可找到Ph染色体,即t(9:22)(q34;q11),并均可检测到BCR—ABL融合基因。酪氨酸激酶抑制剂(TKI)伊马替尼的出现,彻底改变了CML的治疗过程和理念,使CML药物治疗的主要目标从追求症状缓解或血液学反应转变为追求细胞遗传学反应和分子学反应,争取患者获得长期无疾病进展生存并改善生活质量。
作者 江倩 黄晓军
出处 《中华内科杂志》 CAS CSCD 北大核心 2013年第10期803-805,共3页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献13

  • 1杨崇礼,张晓波.全国白血病发病情况调查[J].中国医学科学院学报,1992,14(1):12-19. 被引量:42
  • 2王建祥,黄晓军,吴德沛,胡建达,刘霆,胡豫,孟凡义,陈协群,侯明,李艳,王书杰,王健民,任汉云,于力,陈芳源,邱录贵,江滨,孙爱宁,刘庭波,朱焕玲,郭涛,徐丹,纪春岩,吕晓毅,焦力,宋献民,黄洪晖.中国15家医院慢性粒细胞白血病发病状况及目前诊断治疗模式调查分析[J].中华血液学杂志,2009,30(11):721-725. 被引量:26
  • 3Laneuville P, Bamett MJ, Belanger R, et al. Recommendations ofthe Canadian consensus group on the management of chronicmyeloid leukemia. Curr Oncol,2006,13 :201 -221. 被引量:1
  • 4Wang AH, Wang YY, Yao Y, et al. Summary of 615 patients ofchronic myeloid leukemia in Shanghai from 2001 to 2006. J ExpClin Cancer Res, 2010,29:20. 被引量:1
  • 5Jiang Q,Xu LP,Liu DH,et al. Imatinib results in betteroutcomes than HLA-identical sibling transplants in young personswith newly diagnosed chronic-phase chronic myelogenous leukemia[J/OL]. Leukemia,2013 [ 2013-07-12]. http://www. nature, com/leu/j oumal/ vaop/ncurrent/full/ leu2013159a. html. [ Epub ahead ofprint]. 被引量:1
  • 6Jiang Q, Xu LP, Liu DH, et al. Imatinib mesylate versusallogeneic hematopoietic stem cell transplantation for patients withchronic myelogenous leukemia in the accelerated phase. Blood,2011,117:3032-3040. 被引量:1
  • 7de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib fornewly diagnosed patients with chronic myeloid leukemia : incidenceof sustained responses in an intention-to-treat analysis. J ClinOncol,2008,26:3358-3363. 被引量:1
  • 8Baccarani M,Cortes J,Pane F,et al. Chronic myeloid leukemia:an update of concepts and management recommendations ofEuropean Leukemia Net. J Clin Oncol, 2009,27 : 6041-6051. 被引量:1
  • 9Jiang Q,Zhao XY, Qin YZ, et al. The differences andcorrelations of BCR-ABL transcripts between peripheral blood andbone marrow assays are associated with the molecular responses inthe bone marrow for chronic myelogenous leukemia. Am JHematol ,2012 ,87 : 1065-1069. 被引量:1
  • 10Marin D,Ibrahim AR,Lucas C,et al. Assessment of BCR-ABL1transcript levels at 3 months is the only requirement for predictingoutcome for patients with chronic myeloid leukemia treated withtyrosine kinase inhibitors. J Clin Oncol, 2012,30:232-238. 被引量:1

二级参考文献72

  • 1黄河,蔡真,林茂芳,谢万灼,梁彬,李黎,何静松,罗依,郑伟燕,张洁,叶琇锦,胡晓蓉,陈水云,金爱云.非亲缘异基因骨髓移植治疗儿童白血病[J].中华儿科杂志,2004,42(11):835-839. 被引量:7
  • 2贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量:10
  • 3杨崇礼,邵宗鸿.关于白血病流行病学的一些问题[J].中华血液学杂志,1989,10(12):654-656. 被引量:7
  • 4江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量:39
  • 5North American Association of Central Cancer Registries (2007) North American age-specific invasive cancer incidence rates, chronic myeloid leukemia,2000-2004, http ://www. cancer-rates, info/ naaccr/. 被引量:1
  • 6Laneuville P, Barnett M J, Belanger R, et al. Recommendations of the Canadian consensus group on the management of chronic myeloid leukemia. Curr Oncol,2006,13:201-221. 被引量:1
  • 7O ' Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival ,low rate of transformation and increased rate of major molecular response(MMR) in patients with newly diagnosed chronic myeloid leukemia in chronic phase(CML-CP) treated with imatinib(IM). Blood ,2008,112 : 186a. 被引量:1
  • 8O' Brien S, Berman E, Borghaei H, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Cane Netw, 2009, 7:982-1023. 被引量:1
  • 9NCCN Clinical Practice Guidelines in Oncology (NCCN Guide- lines^TM )-FREE: Chronic Myelogenous Leukemia. Version 2. 2011[ 2011-03-29 ]. http//www. nccn. org/professionals/physi- cian_gls/f_guidelines. asp. 被引量:1
  • 10Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic mycloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108 : 1809-1820. 被引量:1

共引文献138

同被引文献45

  • 1袁长吉,迟宝荣,姚程,易永林.RT-PCR方法检测慢性粒细胞白血病bcr/abl融合基因类型[J].吉林大学学报(医学版),2004,30(5):750-752. 被引量:9
  • 2王强,张成刚,李大魁.伊马替尼用于慢性粒细胞性白血病治疗的药物经济学评价[J].中国药学杂志,2005,40(6):472-474. 被引量:9
  • 3Hehlmann R, Hochhaus A, Baccarani M, et al. Chronic myeloid leu- kaemia[ J]. Lancet, 2007,370(9584) :342 - 350. 被引量:1
  • 4Pasquini MC. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post - tyrosine kinase inhibitor era [ J ]. Hematology, 2012,17 Suppl 1 :S79 -S82. 被引量:1
  • 5Rohrbacher M, Berger U, Hoehhaus A, et al. Clinical trials underesti- mate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR - ABL - positive CML and other chronic myeloproliferative disorders in a representative area in Germany [ J ]. Leukemia, 2009,23(3) :602 -604. 被引量:1
  • 6Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in A- sia[ J]. Int J Hematol, 2009,89( 1 ) : 14 -23. 被引量:1
  • 7Wang AH, Wang YY, Yao Y, et al. Summary of 615 patients of chron- ic myeloid leukemia in Shanghai from 2001 to 2006 [ J ]. J Exp Clin Cancer Res, 2010,29:20. 被引量:1
  • 8Faber E, Kuba A, Zapletalova J, et al. Interferon - alpha in chronic myeloid leukemia revisited : a long - term retrospective study in Central and Northern Moravia[ J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub2013,157 (3) :248 - 256. 被引量:1
  • 9Haznedaroglu IC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European Leukemia Net 2013 recom- mendations[J]. Expert Opin Pharmacother, 2013,14(15) :2005 -2010. 被引量:1
  • 10Gugliotta G, Castagnetti F, Fogli M, et al. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine - kinase inhibi- tors[J]. Expert Rev Hematol, 2013,6(5) :563 -574. 被引量:1

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部